Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

281.00p

Change Today:

-3.00p
52 Week High: 352.00p
52 Week Low: 192.40p

Currency: UK Pounds
Shares Issued: 871.56m
Volume: 30,671

Market Cap: £2,449.09m
RiskGrade: 226
Beta: 1.20

Latest ShareCast News

Hutchmed to receive $20m Fruzaqla milestone payment

By Josh White

Date: Thursday 31 Oct 2024

(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.

Read full story

News Channel

Hutchmed reports positive results from AstraZeneca lung cancer collaboration

By Josh White

Date: Wednesday 16 Oct 2024

(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys', or savolitinib, in treating patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), who had high levels of MET overexpression or amplification and whose disease progressed after treatment with Tagrisso.

Read full story

News Channel

Hutchmed partner Takeda gets Japanese approval for Fruzaqla

By Josh White

Date: Tuesday 24 Sep 2024

(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market 'Fruzaqla', or fruquintinib, for the treatment of previously-treated metastatic colorectal cancer (CRC).

Read full story

News Channel

Hutchmed to present new and updated clinical tri...	09-Sep-2024	ShareCast
Hutchmed withdraws supplemental new drug applica...	30-Aug-2024	ShareCast
Oncology revenue drives first-half growth for Hu...	31-Jul-2024	ShareCast
Hutchmed gets tazemetostat new drug application ...	04-Jul-2024	ShareCast
Hutchmed partner gets European approval for fruq...	24-Jun-2024	ShareCast
Hutchmed publishes positive sovleplenib trial re...	17-Jun-2024	ShareCast
Hutchmed China launches two cancer treatment tri...	14-May-2024	ShareCast
Hutchmed China to make several presentations at ...	05-Apr-2024	ShareCast
Hutchmed endometrial cancer treatment gets prior...	02-Apr-2024	ShareCast
Hutchmed cancer treatment indication accepted fo...	28-Mar-2024	ShareCast
Hutchmed partner Inmagene exercises options over...	02-Feb-2024	ShareCast
Hutchmed's 'Elunate' approved under new Hong Kon...	30-Jan-2024	ShareCast
Hutchmed application for thrombocytopenia treatm...	11-Jan-2024	ShareCast
Hutchmed completes trial enrolment, keeps drugs ...	13-Dec-2023	ShareCast
Hutchmed completes trial enrolment, keeps drugs ...	13-Dec-2023	ShareCast
Hutchmed confirms new drug application for fruqu...	29-Sep-2023	ShareCast
Director dealings: IPF non-exec picks up shares,...	14-Sep-2023	ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

HCM Market Data

Currency	UK Pounds
Share Price	281.00p
Change Today	-3.00p
% Change	-1.06 %
52 Week High	352.00p
52 Week Low	192.40p
Volume	30,671
Shares Issued	871.56m
Market Cap	£2,449.09m
Beta	1.20
RiskGrade	226